title: A cell-permeable fusion protein based on Clostridium botulinum C2 toxin for delivery of p53 tumorsuppressor into cancer cells.
abstract: Genetically engineered bacterial protein toxins are attractive systems for delivery of exogenous proteins into the cytosol of mammalian cells. The binary C2 toxin from C. botulinum has emerged as powerful delivery vehicle, which rests on its binding/translocation component C2IIa and the genetically modified adaptor domain C2IN that act in concert to trigger cell uptake. The p53 tumor suppressor protein has a crucial function in suppressing carcinogenesis and is frequently inactivated by diverse mechanisms in human tumor cells. Therefore, we constructed a C2IN-p53 fusion protein, which is internalized into cancer cells by C2IIa. To this end, the C2IN-p53 fusion construct was overexpressed in E. coli with good solubility, purified by heparin affinity chromatography and protein identity was confirmed by immunoblotting. We demonstrated that the fusion protein is capable of binding to the p53 consensus-DNA with high affinity in a p53-specific manner in vitro. Next, the internalization of C2IN-p53 was monitored in HeLa cells by cell fractionation and immunoblot analysis, which revealed a C2IIa-mediated translocation of the fusion protein into the cytosol. The uptake was also shown in A549 and Saos-2 cells with similar efficiency. These findings were further corroborated by confocal immunofluorescence analyses of C2IN-p53/C2IIa-treated HeLa and A549 cells, displaying predominantly cytoplasmic localization of the fusion construct.
authors.affiliation: Institute of Pharmacology and Toxicology, University of Ulm Medical Center, Ulm, Germany ; Institute of Toxicology, University Medical Center Mainz, Mainz, Germany.
authors.forename: Jörg
authors.initials: J
authors.lastname: Fahrer
authors.forename: Johannes
authors.initials: J
authors.lastname: Rausch
authors.forename: Holger
authors.initials: H
authors.lastname: Barth
mesh_terms: D001905:Botulinum Toxins / Q000302:isolation & purification / Q000378:metabolism*; D002463:Cell Membrane Permeability; D002846:Chromatography, Affinity; D003593:Cytoplasm / Q000378:metabolism; D006367:HeLa Cells; D006801:Humans; D021381:Protein Transport; D011993:Recombinant Fusion Proteins / Q000302:isolation & purification / Q000378:metabolism*; D016159:Tumor Suppressor Protein p53 / Q000302:isolation & purification / Q000378:metabolism*
chemical_list: D011993:Recombinant Fusion Proteins; C495901:TP53 protein, human; D016159:Tumor Suppressor Protein p53; D001905:Botulinum Toxins; C096324:botulinum toxin type C
references.citation: Infect Immun. 1998 Apr;66(4):1364-9
references.pmid: 9529054
references.citation: Nat Cell Biol. 2000 Sep;2(9):563-8
references.pmid: 10980695
references.citation: Oncogene. 2007 Feb 26;26(9):1306-16
references.pmid: 17322916
references.citation: J Biol Chem. 2003 Sep 26;278(39):37360-7
references.pmid: 12869543
references.citation: Proc Natl Acad Sci U S A. 1987 Nov;84(21):7716-9
references.pmid: 2823272
references.citation: Nat Rev Cancer. 2013 Feb;13(2):83-96
references.pmid: 23303139
references.citation: Cell. 1992 Sep 4;70(5):715-28
references.pmid: 1516130
references.citation: Biol Chem. 2010 Nov;391(11):1315-25
references.pmid: 20868225
references.citation: Bioconjug Chem. 2013 Apr 17;24(4):595-603
references.pmid: 23506195
references.citation: Curr Med Chem. 2008;15(5):459-69
references.pmid: 18289001
references.citation: J Biol Chem. 1999 Sep 24;274(39):27407-14
references.pmid: 10488072
references.citation: Cell Microbiol. 2009 May;11(5):780-95
references.pmid: 19159389
references.citation: Cell. 1993 Nov 5;75(3):495-505
references.pmid: 8221889
references.citation: Cell Microbiol. 2012 Aug;14(8):1193-205
references.pmid: 22420783
references.citation: Infect Immun. 2008 Oct;76(10):4600-8
references.pmid: 18710868
references.citation: Bioconjug Chem. 2010 Jan;21(1):130-9
references.pmid: 20030334
references.citation: J Biol Chem. 2002 Feb 15;277(7):5074-81
references.pmid: 11741886
references.citation: Infect Immun. 2009 Dec;77(12):5593-601
references.pmid: 19805536
references.citation: J Cell Biol. 2000 Apr 17;149(2):263-70
references.pmid: 10769020
references.citation: Anticancer Res. 2009 Nov;29(11):4879-85
references.pmid: 20032451
references.citation: Angew Chem Int Ed Engl. 2006 Oct 6;45(39):6440-60
references.pmid: 16983711
references.citation: Infect Immun. 2009 Nov;77(11):5139-48
references.pmid: 19720757
references.citation: Exp Cell Res. 1999 May 1;248(2):457-72
references.pmid: 10222137
references.citation: J Mol Biol. 2006 Dec 8;364(4):705-15
references.pmid: 17027031
references.citation: J Biol Chem. 2007 Apr 6;282(14):10272-82
references.pmid: 17283073
references.citation: Mol Carcinog. 2011 Apr;50(4):222-34
references.pmid: 21465572
references.citation: J Biol Chem. 2003 Aug 22;278(34):32266-74
references.pmid: 12805360
references.citation: Biochemistry. 2003 Dec 30;42(51):15284-91
references.pmid: 14690438
references.citation: Adv Healthc Mater. 2013 Dec;2(12):1620-9
references.pmid: 23657926
references.citation: Cancer Cell. 2007 Oct;12(4):303-12
references.pmid: 17936556
references.citation: Cell. 2009 May 1;137(3):413-31
references.pmid: 19410540
references.citation: Cell Microbiol. 2010 Dec;12(12):1809-20
references.pmid: 20690924
references.citation: Nature. 1986 Jul 24-30;322(6077):390-2
references.pmid: 3736664
references.citation: J Biol Chem. 2000 Jun 23;275(25):18704-11
references.pmid: 10749859
references.citation: Biomaterials. 2012 Sep;33(27):6393-407
references.pmid: 22704599
references.citation: Trends Cell Biol. 2010 Jan;20(1):14-24
references.pmid: 19879762
references.citation: Mol Cell Biol. 2008 Jun;28(12):4129-41
references.pmid: 18411303
references.citation: Biomaterials. 2013 Jul;34(21):5149-62
references.pmid: 23578555
references.citation: Infect Immun. 2000 Aug;68(8):4566-73
references.pmid: 10899856
references.citation: mBio. 2012 May 01;3(3):
references.pmid: 22550037
references.citation: Proc Natl Acad Sci U S A. 1997 Jun 10;94(12):6153-8
references.pmid: 9177186
references.citation: Nature. 1998 Jul 30;394(6692):494-8
references.pmid: 9697774
references.citation: Nat Rev Clin Oncol. 2011 Jan;8(1):25-37
references.pmid: 20975744
references.citation: Mol Cancer Ther. 2008 Jun;7(6):1420-9
references.pmid: 18566214
references.citation: J Biol Chem. 2000 Jan 28;275(4):2328-34
references.pmid: 10644682
references.citation: Mol Pharm. 2012 Oct 1;9(10):2887-93
references.pmid: 22894610
references.citation: Methods Mol Biol. 2003;234:17-28
references.pmid: 12824522
references.citation: Nat Rev Cancer. 2006 Dec;6(12):909-23
references.pmid: 17128209